Many patients ask: “My pressure is normal. Why do I still need treatment?” The answer lies in understanding glaucoma progression.
Glaucoma is not diagnosed or managed using a single test or single number, explains Dr Bhartiya. It is assessed over time by looking at:
- Optic nerve structure (OCT scans)
- Functional vision (visual fields)
- Eye pressure trends
- Individual risk factors
Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.
What does “stable” mean?
Stability does not mean nothing is happening.
It means that any change is slow enough not to affect your quality of life over decades.
A patient can have:
This is why follow-up testing is essential even when pressure readings look good.
Why progression is often silent
The brain compensates remarkably well for early visual field loss. Most patients do not notice change until damage is advanced – when options become limited.
Detecting progression early allows:
- Adjusting treatment before irreversible loss
- Avoiding emergency surgery later
- Preserving driving, reading, and independence
Glaucoma is probabilistic, not binary
There is no single threshold that guarantees safety. Care is based on risk stratification, not absolutes. This is why personalised follow-up schedules and targets matter. This is also why Understanding Glaucoma Progression is so critical to preserving vision related quality of life.
Known for her structured approach to glaucoma risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions.
Glaucoma Treatment Options: Drops, Laser, and Surgery
Glaucoma treatment is not one-size-fits-all. The right choice depends on stage, risk profile, anatomy, lifestyle, and long-term goals.
1. Medical treatment (eye drops)
Often the first step, especially in early disease.
Pros
- Non-invasive
- Effective when used consistently
Limitations
- Lifelong adherence required
- Side effects and drop fatigue
- Missed doses reduce protection
Drops work well when patients and systems support consistency.
2. Laser treatment (e.g. SLT)
Laser can reduce eye pressure and drop burden.
Pros
- Day-care procedure
- Can delay or reduce need for drops
Limitations
- Effect varies between individuals
- Not permanent in all cases
Laser is a tool, not a cure.
3. Surgery
Reserved for advanced disease or progression despite treatment.
Pros
- Greater pressure lowering
- Long-term control in selected cases
Limitations
- Higher risk
- Requires close follow-up
Surgery works best when chosen before crisis, not as a last resort.
The key principle of understanding glaucoma progression
The goal is not the “strongest” treatment – it is the right treatment at the right time.
How fast does glaucoma progress?
This is one of the most important — and most variable — questions in glaucoma care.
Some patients progress rapidly despite treatment. Others remain stable for decades on minimal medication. Most fall somewhere between.
Rate of progression depends on:
- Baseline pressure and how much it is reduced by treatment
- Optic nerve vulnerability — some nerves sustain damage at lower pressures
- Age — older patients with advanced disease at diagnosis have less time to accumulate further damage before functional impact
- Vascular factors — blood flow to the optic nerve matters independently of pressure
- Consistency of treatment and follow-up
This variability is precisely why glaucoma cannot be managed with a fixed protocol. It requires individual risk assessment, individual targets, and monitoring intervals tailored to how fast each patient’s disease is moving.
A patient progressing quickly needs more frequent visits and more aggressive pressure control. A patient who has been stable for five years on a single drop can reasonably be monitored less intensively. The schedule should match the disease — not the other way around.
Frequently Asked Questions: Glaucoma Progression
What does it mean when my doctor says my glaucoma is stable?
Stability in glaucoma does not mean nothing is happening. It means that any change occurring is slow enough that it is unlikely to affect your quality of life during your lifetime. A patient can have entirely normal pressure readings but still show worsening on OCT or visual field tests. Conversely, a patient with higher pressure may remain structurally and functionally stable for years. Stability is a trend conclusion — it requires multiple tests over time to establish, not a single good result.
My pressure is normal. Why does my doctor say glaucoma is progressing?
Eye pressure is one input, not the whole picture. Glaucoma is assessed using optic nerve structure on OCT scans, functional vision on visual field tests, and pressure trends together. Some patients — particularly those with normal tension glaucoma — sustain nerve damage at statistically normal pressure levels. If your OCT or visual field shows change over time, that is progression — regardless of what the pressure reading says on any given day.
How quickly does glaucoma progress?
Progression rate varies enormously between patients. Some progress rapidly despite treatment. Others remain stable for decades. The rate depends on how much pressure reduction is achieved, how vulnerable the optic nerve is, age, vascular health, and how consistently treatment is followed. This is why glaucoma cannot be managed with a single fixed protocol. Monitoring intervals and treatment targets need to match each patient’s individual rate of change.
How is glaucoma progression detected?
Progression is detected by comparing tests over time — not by a single abnormal result. The key tools are OCT scans, which measure optic nerve fibre thickness, and visual field tests, which measure functional vision. A single result that looks worse than the previous one may reflect test variability. A consistent trend across multiple visits is what constitutes progression. This is why longitudinal data — keeping all your old reports — matters so much.
Can glaucoma progress even if I am taking my drops?
Yes. Drops reduce eye pressure but do not stop all progression in every patient. If pressure is not reduced enough to reach your individual target, nerve damage can continue. If drops are missed regularly, the protection they offer is reduced. In some patients, the pressure target needs to be lowered further, or laser or surgery considered, because drops alone are not providing adequate control. Progression on treatment is a signal to reassess — not to simply wait.
What happens if glaucoma is detected early but left untreated?
Untreated glaucoma will typically progress. The rate depends on the individual, but the direction of travel without intervention is towards worsening nerve damage and, eventually, vision loss. Early detection is valuable precisely because it creates time to intervene before damage becomes functionally significant. The earlier treatment begins in most cases, the more vision can be protected over the long term.
How often should glaucoma be monitored?
Monitoring frequency should be matched to the individual’s rate of progression and risk profile. A newly diagnosed patient, or one showing progression, needs more frequent visits — often every three to four months initially. A patient who has been stable for several years on established treatment may need visits every six to twelve months. The schedule should be set by your glaucoma specialist based on your specific situation — not by a standard timetable applied to everyone.
When should glaucoma treatment be escalated?
Treatment should be escalated when documented progression occurs despite current therapy, when pressure remains above the individualised target, or when risk factors suggest the current plan is not providing adequate protection. Escalation might mean adding a second drop, switching to laser, or considering surgery. The decision is based on the evidence of change in your specific case — not on pressure thresholds alone or on how you feel.
What is the difference between structural and functional glaucoma progression?
Structural progression refers to measurable changes in the optic nerve on OCT scans — thinning of nerve fibre layers that can be detected before any vision loss is noticed. Functional progression refers to changes on visual field tests — measurable loss of peripheral vision. Structural changes typically precede functional ones by years. This is why OCT monitoring is so valuable in early glaucoma — it detects change before you would ever feel it.
Read the research articles
This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. This article was edited in April 2026.
She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.
As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.
Her work can be accessed on Pubmed, Google Scholar, ResearchGate and ORCID.
Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care
www.drshibalbhartiya.com
+91 88826 38735
1500+ Five Star Patient Reviews Google Business Profile
